<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476463</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 023</org_study_id>
    <nct_id>NCT00476463</nct_id>
  </id_info>
  <brief_title>Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection</brief_title>
  <official_title>Virological and Clinical Anti-HBV Efficacy of Tenofovir and Emtricitabine in Antiretroviral Naive Patients With HIV/HBV Co-infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination therapy with anti-HBV activity may both increase HBV suppression rates and reduce
      emergence of resistant strains. Several new therapeutic agents are currently in development,
      however combination therapy trials in the HBV-infected population have only recently
      commenced. No such trials have been undertaken in the HIV/HBV co-infected population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study objective is to compare HBV DNA suppression to levels below the limit of
      detection (&lt;400 copies/ml) by week 48 in each treatment group. Virological and clinical
      anti-HBV efficacy of tenofovir and emtricitabine in antiretroviral naive patients with
      HIV/HBV co-infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV DNA suppression to levels below the limit of detection (&lt;400 copies/ml)</measure>
    <time_frame>week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV suppression as measured by comparison of AUC measurements at 12 and 24 weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with undetectable HBV DNA in serum at 12 and 24 weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of HBeAg and HBsAg seroconversion at 12, 24 and 48 weeks.</measure>
    <time_frame>12, 24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of emergence of LAM-resistant HBV genotypes at 48 weeks.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hepatic cytolysis (ALT level &gt; 5x ULN).</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ALT levels and time to ALT normalization.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of plasma HIV-RNA (&lt; 50 copies/ml) through 48 weeks.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4+ /CD8+ cell counts through 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of effect of therapy on histological changes in the liver and effect on ccc-HBV-DNA</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatitis B Virus</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZT+FTC+EFV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TDF+FTC+EFV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Documented HIV infection (positive serology for HIV-1 and detectable HIV-1 RNA)

          -  Age 18 - 70 years

          -  HBV DNA &gt; 106 copies/ml

          -  HBsAg positive for &gt; 6 months

        In case documented duration of HBsAg seropositive is less than 6 months (this situation is
        most likely to occur in patients newly presenting to the HIV-outpatient clinic) the patient
        is eligible if the patient is:

          1. HBsAg positive and

          2. HBc core IgM antibody negative and

          3. the liver biopsy gives evidence for a chronic active hepatitis. Thus making it likely
             that this patient has acquired the HBV infection more than 6 months ago.

               -  ALT &lt; 10 x ULN

               -  Creatinine &lt;= 2.0mg/dl

               -  Platelet count &gt;= 50,000/mm3

               -  HIV-1 therapy naive

               -  No prior exposure to anti-HBV agents (LAM, adefovir, TDF) although prior IFN
                  treatment allowed

        Exclusion Criteria:

          -  HCV-RNA positive or Anti-HAV IgM positive

          -  Acute hepatitis (serum ALT &gt; 1000 U/L)

          -  Prior LAM, TDF, or ADV therapy

          -  Active opportunistic infection

          -  Other causes of chronic liver disease identified ( autoimmune hepatitis,
             haemochromatosis, Wilsons disease, alfa-1-antitrypsin deficiency)

          -  Concurrent malignancy requiring cytotoxic chemotherapy

          -  Decompensated or Child's C cirrhosis

          -  Alfa-fetoprotein (AFP) &gt; 3X ULN (unless negative CT scan or MRI within 3 months of
             entry date)

          -  Pregnancy or lactation

          -  Any other condition which in the opinion of the investigator might interfere with
             compliance or outcome of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiat Ruxrungtham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIV-NAT Thai Red Cross AIDS Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIV-NAT Thai Red Cross AIDS Research Center</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2007</study_first_submitted>
  <study_first_submitted_qc>May 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TDF+FTC</keyword>
  <keyword>FTC</keyword>
  <keyword>HIV/HBV</keyword>
  <keyword>TDF compared to TDF+FTC in HIV/HBV</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

